Dirk-Jan van Beek1, Sjoerd Nell2, Helena M Verkooijen3, Inne H M Borel Rinkes1, Gerlof D Valk4, Menno R Vriens1. 1. Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. 2. Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. 3. Imaging Division, University Medical Center Utrecht, Utrecht, the Netherlands. 4. Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Abstract
BACKGROUND: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related insulinomas and assessed factors associated with prognosis. METHODS: Patients who underwent resection of a multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors between 1990 and 2016 were identified in 2 databases: the DutchMEN Study Group and the International MEN1 Insulinoma Study Group databases. Cox regression was performed to compare liver metastases-free survival of patients with a nonfunctioning pancreatic neuroendocrine tumors versus those with an insulinoma and to identify factors associated with liver metastases-free survival. RESULTS: Out of 153 patients with multiple endocrine neoplasia type 1, 61 underwent resection for a nonfunctioning pancreatic neuroendocrine tumor and 92 for an insulinoma. Of the patients with resected lymph nodes, 56% (18/32) of nonfunctioning pancreatic neuroendocrine tumors had lymph node metastases compared to 10% (4/41) of insulinomas (P = .001). Estimated 10-year liver metastases-free survival was 63% (95% confidence interval 42%-76%) for nonfunctioning pancreatic neuroendocrine tumors and 87% (72%-91%) for insulinomas. After adjustment for size, World Health Organization tumor grade, and age, nonfunctioning pancreatic neuroendocrine tumors had an increased risk for liver metastases or death (hazard ratio 3.04 [1.47-6.30]). In pancreatic neuroendocrine tumors ≥2 cm, nonfunctioning pancreatic neuroendocrine tumors (2.99 [1.22-7.33]) and World Health Organization grade 2 (2.95 [1.02-8.50]) were associated with liver metastases-free survival. CONCLUSION: Patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors had a significantly lower liver metastases-free survival than patients with insulinomas. Postoperative counseling and follow-up regimens should be tumor type specific and at least consider size and World Health Organization grade.
BACKGROUND: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related insulinomas and assessed factors associated with prognosis. METHODS: Patients who underwent resection of a multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors between 1990 and 2016 were identified in 2 databases: the DutchMEN Study Group and the International MEN1 Insulinoma Study Group databases. Cox regression was performed to compare liver metastases-free survival of patients with a nonfunctioning pancreatic neuroendocrine tumors versus those with an insulinoma and to identify factors associated with liver metastases-free survival. RESULTS: Out of 153 patients with multiple endocrine neoplasia type 1, 61 underwent resection for a nonfunctioning pancreatic neuroendocrine tumor and 92 for an insulinoma. Of the patients with resected lymph nodes, 56% (18/32) of nonfunctioning pancreatic neuroendocrine tumors had lymph node metastases compared to 10% (4/41) of insulinomas (P = .001). Estimated 10-year liver metastases-free survival was 63% (95% confidence interval 42%-76%) for nonfunctioning pancreatic neuroendocrine tumors and 87% (72%-91%) for insulinomas. After adjustment for size, World Health Organization tumor grade, and age, nonfunctioning pancreatic neuroendocrine tumors had an increased risk for liver metastases or death (hazard ratio 3.04 [1.47-6.30]). In pancreatic neuroendocrine tumors ≥2 cm, nonfunctioning pancreatic neuroendocrine tumors (2.99 [1.22-7.33]) and World Health Organization grade 2 (2.95 [1.02-8.50]) were associated with liver metastases-free survival. CONCLUSION: Patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors had a significantly lower liver metastases-free survival than patients with insulinomas. Postoperative counseling and follow-up regimens should be tumor type specific and at least consider size and World Health Organization grade.
Authors: C R C Pieterman; E B Conemans; K M A Dreijerink; J M de Laat; H Th M Timmers; M R Vriens; G D Valk Journal: Endocr Relat Cancer Date: 2014-05-06 Impact factor: 5.678
Authors: Elfi B Conemans; Lodewijk A A Brosens; Gabriela M Raicu-Ionita; Carolina R C Pieterman; Wouter W de Herder; Olaf M Dekkers; Ad R Hermus; Anouk N van der Horst-Schrivers; Peter H Bisschop; Bas Havekes; Madeleine L Drent; H Th Marc Timmers; G Johan Offerhaus; Gerlof D Valk; Menno R Vriens Journal: Pancreatology Date: 2017-07-31 Impact factor: 3.996
Authors: P Goudet; C Bonithon-Kopp; A Murat; P Ruszniewski; P Niccoli; F Ménégaux; G Chabrier; F Borson-Chazot; A Tabarin; P Bouchard; G Cadiot; A Beckers; I Guilhem; O Chabre; P Caron; H Du Boullay; B Verges; C Cardot-Bauters Journal: Eur J Endocrinol Date: 2011-05-06 Impact factor: 6.664
Authors: Carolina R C Pieterman; Joanne M de Laat; Jos W R Twisk; Rachel S van Leeuwaarde; Wouter W de Herder; Koen M A Dreijerink; Ad R M M Hermus; Olaf M Dekkers; Anouk N A van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bastiaan Havekes; Inne H M Borel Rinkes; Menno R Vriens; Gerlof D Valk Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: Sjoerd Nell; Helena M Verkooijen; Carolina R C Pieterman; Wouter W de Herder; Ad R Hermus; Olaf M Dekkers; Anouk N van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Inne H M Borel Rinkes; Menno R Vriens; Gerlof D Valk Journal: Ann Surg Date: 2018-06 Impact factor: 12.969
Authors: Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter Journal: BMJ Date: 2009-06-29
Authors: M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen Journal: Neuroendocrinology Date: 2016-01-05 Impact factor: 4.914
Authors: Philip E Cryer; Lloyd Axelrod; Ashley B Grossman; Simon R Heller; Victor M Montori; Elizabeth R Seaquist; F John Service Journal: J Clin Endocrinol Metab Date: 2008-12-16 Impact factor: 5.958
Authors: Dirk-Jan van Beek; Wessel M C M Vorselaars; Inne H M Borel Rinkes; Menno R Vriens Journal: Ann Surg Oncol Date: 2021-01-27 Impact factor: 5.344
Authors: Johannes F Fahrmann; Amanda R Wasylishen; Carolina R C Pieterman; Ehsan Irajizad; Jody Vykoukal; Eunice Murage; Ranran Wu; Jennifer B Dennison; Hansini Krishna; Christine B Peterson; Guillermina Lozano; Hua Zhao; Kim-Anh Do; Daniel M Halperin; Sunita K Agarwal; Jenny E Blau; Jaydira Del Rivero; Naris Nilubol; Mary F Walter; James M Welch; Lee S Weinstein; Menno R Vriens; Rachel S van Leeuwaarde; Mark J C van Treijen; Gerlof D Valk; Nancy D Perrier; Samir M Hanash Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134